Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

November 6, 2018 6 November, 2018

Sernova Establishes Comprehensive North American Investor Relations and Communications Strategy

US Program to Focus on Raising Company’s Visibility Through Engagement of Solebury Trout

Source: Sernova Corp November 6, 2018 6:00 a.m. EST

LONDON, ONTARIO, November 6, 2018 – Sernova Corp (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine company, today announced it has engaged Solebury Trout ("Trout"), a New York- based investor relations and strategic advisory consultant serving life science companies.

Solebury Trout will develop and implement a comprehensive investor outreach program tailored to and in collaboration with Sernova that will include analyst and institutional and retail investor targeting/outreach, non- deal roadshows, corporate communications, and Key Opinion Leader (KOL) events in the chronic disease space.

“We have made significant progress in our diabetes program this year by advancing our US Phase I/II human clinical study of Sernova’s Cell Pouch™ with insulin-producing cells and by announcing the HemAcure Consortium’s achievements in developing a novel cell-based therapy for Hemophilia A. At this important juncture in the Company’s history, the engagement of Solebury Trout advances our strategic initiative to expand awareness of Sernova in the investment community, particularly among US institutional investors,” said Dr. Philip Toleikis, Chief Executive Officer of Sernova. “The team at Trout, with its capital market and institutional experience, brings capabilities that will enable us to present Sernova’s compelling story to a wide audience of investors, both in the U.S. and internationally.”

“Sernova has the potential to transform the diabetes, hemophilia and other chronic diseases treatment landscape with their disruptive regenerative medicine technologies and Solebury Trout will provide Sernova with its biotechnology and life sciences industry experience.” Stated Danny Matthews, Senior Associate at Solebury Trout.

Under the terms of the engagements, Solebury Trout has been retained for an extendable 12-month period for a monthly remuneration of US$16,500 plus direct expenses. Solebury Trout does not currently have any interest, either directly or indirectly, in the company. The agreement is subject to approval by the TSX Venture Exchange.

About Solebury Trout

Solebury Trout provides clients with senior counsel and execution on investor relations and corporate communications strategies. The firm's global reach extends through a network of offices in New York, Boston, Stamford and San Francisco, as well as consultants in the U.K., connecting clients with the right investors and media in all the major financial centers. A highly-experienced team of 60 senior professionals has expertise in investor relations, equity research, portfolio management, private equity, investment banking, journalism and corporate communications. Solebury Trout is affiliated with Solebury Capital, the leading equity capital markets advisory firm, and is a subsidiary of The PNC Financial Services Group, Inc.

About Sernova’s Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, proprietary stem cell- derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device, designed to eliminate concerns of fibrosis upon implantation incorporates with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for survival of insulin-producing cells in humans. Sernova is undertaking a Phase I/II clinical trial of the Cell Pouch with therapeutic cells for diabetes at the University of Chicago.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Danny Matthews, Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

Dominic Gray Communications Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.